Corcept moves to dismiss Teva's amended US antitrust claims over Korlym
MLex Summary: Corcept and Optime told a US federal judge that neither of them is to blame for Teva Pharmaceuticals' limited success for its generic version of the branded Cushing's disease...To view the full article, register now.
Already a subscriber? Click here to view full article